Last reviewed · How we verify
Hydrocortisone/ Placebo and Propranolol
This combination uses hydrocortisone (a glucocorticoid) and propranolol (a beta-blocker) to suppress inflammatory and adrenergic responses, with placebo control to assess efficacy.
This combination uses hydrocortisone (a glucocorticoid) and propranolol (a beta-blocker) to suppress inflammatory and adrenergic responses, with placebo control to assess efficacy. Used for Acute myocardial infarction or acute coronary syndrome (investigational combination).
At a glance
| Generic name | Hydrocortisone/ Placebo and Propranolol |
|---|---|
| Sponsor | University of Dundee |
| Drug class | Glucocorticoid + Beta-blocker combination |
| Target | Glucocorticoid receptor; Beta-1 and Beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Hydrocortisone reduces inflammation and immune activation by binding glucocorticoid receptors, while propranolol blocks beta-adrenergic signaling to reduce heart rate and blood pressure. The placebo arm allows for controlled assessment of the active agents' contribution to clinical outcomes in the studied condition.
Approved indications
- Acute myocardial infarction or acute coronary syndrome (investigational combination)
Common side effects
- Hypoglycemia
- Bradycardia
- Fatigue
- Hyperglycemia
- Infection risk (from immunosuppression)
Key clinical trials
- The Effects of Propranolol, Hydrocortisone, and Morphine on Military-Relevant Performance Outcomes (PHASE4)
- Reversal of Acute β-Blocker Induced Bronchoconstriction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrocortisone/ Placebo and Propranolol CI brief — competitive landscape report
- Hydrocortisone/ Placebo and Propranolol updates RSS · CI watch RSS
- University of Dundee portfolio CI